Significance of MDM2 and P14ARF polymorphisms in susceptibility to differentiated thyroid carcinoma

Surgery (United States)

Volumn 153, Issue 5, 2013, Pages 711-717

  Zhang, Fenghua ^a,b   Xu, Li ^a   Wei, Qingyi ^a   Song, Xicheng ^a,c   Sturgis, Erich M ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b HEBEI GENERAL HOSPITAL   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCINE; PROTEIN MDM2; PROTEIN P14; THREONINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF; YOUNG ADULT;

EID: 84876414239     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.11.009     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. E.P. Simard, E.M. Ward, R. Siegel, and A. Jemal Cancers with increasing incidence trends in the United States: 1999 through 2008 CA Cancer J Clin 62 2012 118 128
3. E. Ron, J.H. Lubin, R.E. Shore, K. Mabuchi, B. Modan, and L.M. Pottern Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies Radiat Res 141 1995 259 277
4. M.N. Nikiforova, and Y.E. Nikiforov Molecular diagnostics and predictors in thyroid cancer Thyroid 19 2009 1351 1361
5. H.F. Horn, and K.H. Vousden Coping with stress: multiple ways to activate p53 Oncogene 26 2007 1306 1316
6. T. Soussi, C. Ishioka, M. Claustres, and C. Beroud Locus-specific mutation databases: pitfalls and good practice based on the p53 experience Nat Rev Cancer 6 2006 83 90
7. B. Shahedian, Y. Shi, M. Zou, and N.R. Farid Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations Mol Genet Metab 72 2001 155 163
8. S. Horie, H. Maeta, K. Endo, T. Ueta, K. Takashima, and T. Terada Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features Pathol Int 51 2001 11 15
9. A. Ferru, G. Fromont, H. Gibelin, J. Guilhot, F. Savagner, and J.M. Tourani The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression Br J Cancer 95 2006 1670 1677
10. A. Prodosmo, S. Giglio, S. Moretti, F. Mancini, F. Barbi, and N. Avenia Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties J Mol Med (Berl) 86 2008 585 596
11. D.A. Freedman, L. Wu, and A.J. Levine Functions of the MDM2 oncoprotein Cell Mol Life Sci 55 1999 96 107
12. P. Ozenne, B. Eymin, E. Brambilla, and S. Gazzeri The ARF tumor suppressor: structure, functions and status in cancer Int J Cancer 127 2010 2239 2247
13. F.J. Stott, S. Bates, M.C. James, B.B. McConnell, M. Starborg, and S. Brookes The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2 Embo J 17 1998 5001 5014
14. S. Ries, C. Biederer, D. Woods, O. Shifman, S. Shirasawa, and T. Sasazuki Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF Cell 103 2000 321 330
15. R. Sreeramaneni, A. Chaudhry, M. McMahon, C.J. Sherr, and K. Inoue Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor Mol Cell Biol 25 2005 220 232
16. B. Eymin, P. Claverie, C. Salon, C. Brambilla, E. Brambilla, and S. Gazzeri p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation Cell Cycle 5 2006 759 765
17. I. Palmero, C. Pantoja, and M. Serrano p19ARF links the tumour suppressor p53 to Ras Nature 395 1998 125 126
18. T. Iwakuma, and G. Lozano MDM2, an introduction Mol Cancer Res 1 2003 993 1000
19. X. Wo, D. Han, H. Sun, Y. Liu, X. Meng, and J. Bai MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis J Genet Genomics 38 2011 341 350
20. Y. Zhang, E.M. Sturgis, M.E. Zafereo, Q. Wei, and G. Li p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck Cancer 117 2011 1227 1235
21. H. Yu, Y.J. Huang, Z. Liu, L.E. Wang, G. Li, and E.M. Sturgis Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck Mol Carcinog 50 2011 697 706
22. G. Li, X. Zhai, Z. Zhang, R.M. Chamberlain, M.R. Spitz, and Q. Wei MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis Carcinogenesis 27 2006 2028 2033
23. Z. Wang, E.M. Sturgis, Y. Zhang, Z. Huang, Q. Zhou, and Q. Wei Combined p53-related genetic variants together with HPV infection increase oral cancer risk Int J Cancer 131 2012 E251 E258
24. M. Wang, Z. Zhang, H. Zhu, G. Fu, S. Wang, and D. Wu A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population Clin Cancer Res 14 2008 3633 3640
25. A.L. Sherborne, F.J. Hosking, R.B. Prasad, R. Kumar, R. Koehler, and J. Vijayakrishnan Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk Nat Genet 42 2010 492 494
26. T. Ho, G. Li, J. Lu, C. Zhao, Q. Wei, and E.M. Sturgis Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis Thyroid 19 2009 129 135
27. L. Xu, P.C. Doan, Q. Wei, Y. Liu, G. Li, and E.M. Sturgis Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma Thyroid 22 2011 35 43
28. X. Zhang, X. Miao, Y. Guo, W. Tan, Y. Zhou, and T. Sun Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer Hum Mutat 27 2006 110 117
29. N. Kreiger, and R. Parkes Cigarette smoking and the risk of thyroid cancer Eur J Cancer 36 2000 1969 1973
30. O.P. Soldin, B.E. Goughenour, S.Z. Gilbert, H.J. Landy, and S.J. Soldin Thyroid hormone levels associated with active and passive cigarette smoking Thyroid 19 2009 817 823
31. G.L. Bond, W. Hu, E.E. Bond, H. Robins, S.G. Lutzker, and N.C. Arva A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 2004 591 602
32. T.R. Rebbeck, M. Spitz, and X. Wu Assessing the function of genetic variants in candidate gene association studies Nat Rev Genet 5 2004 589 597
33. M. Di Vito, E. De Santis, G.A. Perrone, E. Mari, M.C. Giordano, and E. De Antoni Overexpression of estrogen receptor-alpha in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology Cancer Sci 102 2011 1921 1927
34. H.K. Kinyamu, and T.K. Archer Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol Cell Biol 23 2003 5867 5881
35. G.L. Bond, K.M. Hirshfield, T. Kirchhoff, G. Alexe, E.E. Bond, and H. Robins MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 66 2006 5104 5110
36. G.L. Bond, C. Menin, R. Bertorelle, P. Alhopuro, L.A. Aaltonen, and A.J. Levine MDM2 SNP309 accelerates colorectal tumour formation in women J Med Genet 43 2006 950 952
37. C.I. Amos, L.E. Wang, J.E. Lee, J.E. Gershenwald, W.V. Chen, and S. Fang Genome-wide association study identifies novel loci predisposing to cutaneous melanoma Hum Mol Genet 20 2011 5012 5023
38. E.M. Sturgis, and G. Li Molecular epidemiology of papillary thyroid cancer: in search of common genetic associations Thyroid 19 2009 1031 1034